Critical Outcome Tec (COTQF) 0.1790 $COTQF
Financing Increases Runway to the Clinic for COTI-2, Critical Outcome's Lead Cancer Drug Candidate
Marketwire - Thu May 01, 7:50AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Corporation"
the bioinformatics and accelerated drug discovery company, is pleased to announce the completion of a non-brokered private placement of 3,356,250 units (the "Units" at a price of $0.16 per Unit for gross proceeds of $537,000.
Critical Outcome Technologies Applies for Orphan Drug Designation for COTI-2 Treatment of Ovarian Cancer
Marketwire Canada - Fri Apr 04, 8:00AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE:COT), the bioinformatics and accelerated drug discovery company, announced today it has submitted an Orphan Drug Application to the U.S. Food and Drug Administration (FDA) for its lead cancer drug candidate, COTI-2, for the treatment of ovarian cancer.
Critical Outcome Technologies Reports Third Quarter Results
Marketwire - Fri Mar 14, 8:02AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Company", the bioinformatics and accelerated drug discovery company, reported its financial and operating results today for the three and nine month periods ended January 31, 2014.
Critical Outcome Technologies Inc. Announces Warrant Term Amendment
Marketwire - Fri Mar 07, 3:31PM CST
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT) announced today that it has received acceptance from the TSX Venture Exchange ("TSXV" to extend the expiry term of 1,575,500 common share purchase warrants ("Warrants" issued as part of its private placement in April and May 2010 representing the third amendment made for these warrants.
Critical Outcome Technologies Identifies Experienced Partner for Clinical Development of COTI-2
Marketwire - Wed Feb 26, 8:31AM CST
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that it has signed a non-binding letter of intent ("LOI" to form a joint venture with Portage Biotech Inc. ("Portage", a British Virgin Island incorporated public company, listed and traded on the Canadian Securities Exchange ("PTB.U", and on NASDAQ and the OTC ("PTGEF" to fund and direct the Phase 1 development of the Company's clinical oncology candidate, COTI-2.
Critical Outcome Technologies Completes Private Placement
Marketwire - Thu Feb 06, 8:14AM CST
Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Corporation", the bioinformatics and accelerated drug discovery company, announced today that it has completed an arm's length non-brokered private placement raising approximately $500,000 consisting of a non-convertible debenture (the "Debenture" in the amount of $400,000 and an equity placement of 769,230 units (the "Units" at a price of $0.13 per Unit for approximately $100,000.
New York Mortgage Trust Announces Tax Treatment of Common Stock Dividends for 2013
GlobeNewswire - Fri Jan 31, 3:01PM CST
New York Mortgage Trust, Inc. (Nasdaq:NYMT) ("NYMT" or the "Company" today announced the following tax treatment for dividends declared in 2013 on the Company's common stock.
Catlin Buys 22.5% Stake in Russian Re From AIG
Michael Buck - AMBest - Fri Jan 31, 2:42PM CST
A subsidiary of Catlin Group Ltd. has purchased a 22.5% stake in Russian Reinsurance Co. from American International Group.
Critical Outcome Technologies Reports Second Quarter Results
Marketwire - Wed Dec 18, 3:49PM CST
Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Company" reported its financial and operating results today for the three and six month periods ended October 31, 2013.
Critical Outcome Technologies Awards Stock Options
Marketwire - Fri Dec 06, 3:05PM CST
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, announced today that it awarded 971,168 stock options to directors and officers under the Company's Stock Option Plan. The options awarded to directors were made as a retainer for their service on the Board and its committees for the ensuing year. The options have a five year life with 25% vesting occurring at the end of each quarter from the date of grant. The exercise price is $0.18 and represents the closing price of the Company's common shares on December 4, 2013, the last trading day reported on the TSX Venture Exchange prior to the meeting date.
Critical Outcome Technologies Provides Business and Scientific Update at Annual General Meeting
Marketwire - Fri Dec 06, 7:47AM CST
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, announced today that its President & Chief Executive Officer, Dr. Wayne Danter, provided a business and scientific developments update of the Company at its Annual General and Special Meeting (AGM) of Shareholders held on Thursday, December 5, 2013.
COTI-2, a P53 Dependent Treatment for Many Common Cancers, Receives Additional U.S. Patent Protection
Marketwire - Wed Nov 13, 8:03AM CST
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that the United States ("U.S." Patent and Trademark Office has recently granted an additional patent for the Company's lead oncology asset, COTI-2. COTI-2 now has five U.S. patents granted, with several more pending.
Financing Increases Runway to the Clinic for COTI-2, Critical Outcome's Lead Cancer Drug Candidate
Marketwire - Thu May 01, 7:50AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Corporation"
the bioinformatics and accelerated drug discovery company, is pleased to announce the completion of a non-brokered private placement of 3,356,250 units (the "Units" at a price of $0.16 per Unit for gross proceeds of $537,000. Critical Outcome Technologies Applies for Orphan Drug Designation for COTI-2 Treatment of Ovarian Cancer
Marketwire Canada - Fri Apr 04, 8:00AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE:COT), the bioinformatics and accelerated drug discovery company, announced today it has submitted an Orphan Drug Application to the U.S. Food and Drug Administration (FDA) for its lead cancer drug candidate, COTI-2, for the treatment of ovarian cancer. Critical Outcome Technologies Reports Third Quarter Results
Marketwire - Fri Mar 14, 8:02AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Company"
, the bioinformatics and accelerated drug discovery company, reported its financial and operating results today for the three and nine month periods ended January 31, 2014. Critical Outcome Technologies Inc. Announces Warrant Term Amendment
Marketwire - Fri Mar 07, 3:31PM CST
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT) announced today that it has received acceptance from the TSX Venture Exchange ("TSXV"
to extend the expiry term of 1,575,500 common share purchase warrants ("Warrants" issued as part of its private placement in April and May 2010 representing the third amendment made for these warrants. Critical Outcome Technologies Identifies Experienced Partner for Clinical Development of COTI-2
Marketwire - Wed Feb 26, 8:31AM CST
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that it has signed a non-binding letter of intent ("LOI" to form a joint venture with Portage Biotech Inc. ("Portage", a British Virgin Island incorporated public company, listed and traded on the Canadian Securities Exchange ("PTB.U", and on NASDAQ and the OTC ("PTGEF" to fund and direct the Phase 1 development of the Company's clinical oncology candidate, COTI-2. Critical Outcome Technologies Completes Private Placement
Marketwire - Thu Feb 06, 8:14AM CST
Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Corporation"
, the bioinformatics and accelerated drug discovery company, announced today that it has completed an arm's length non-brokered private placement raising approximately $500,000 consisting of a non-convertible debenture (the "Debenture" in the amount of $400,000 and an equity placement of 769,230 units (the "Units" at a price of $0.13 per Unit for approximately $100,000. New York Mortgage Trust Announces Tax Treatment of Common Stock Dividends for 2013
GlobeNewswire - Fri Jan 31, 3:01PM CST
New York Mortgage Trust, Inc. (Nasdaq:NYMT) ("NYMT" or the "Company"
today announced the following tax treatment for dividends declared in 2013 on the Company's common stock. Catlin Buys 22.5% Stake in Russian Re From AIG
Michael Buck - AMBest - Fri Jan 31, 2:42PM CST
A subsidiary of Catlin Group Ltd. has purchased a 22.5% stake in Russian Reinsurance Co. from American International Group.
Critical Outcome Technologies Reports Second Quarter Results
Marketwire - Wed Dec 18, 3:49PM CST
Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Company"
reported its financial and operating results today for the three and six month periods ended October 31, 2013. Critical Outcome Technologies Awards Stock Options
Marketwire - Fri Dec 06, 3:05PM CST
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, announced today that it awarded 971,168 stock options to directors and officers under the Company's Stock Option Plan. The options awarded to directors were made as a retainer for their service on the Board and its committees for the ensuing year. The options have a five year life with 25% vesting occurring at the end of each quarter from the date of grant. The exercise price is $0.18 and represents the closing price of the Company's common shares on December 4, 2013, the last trading day reported on the TSX Venture Exchange prior to the meeting date.
Critical Outcome Technologies Provides Business and Scientific Update at Annual General Meeting
Marketwire - Fri Dec 06, 7:47AM CST
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, announced today that its President & Chief Executive Officer, Dr. Wayne Danter, provided a business and scientific developments update of the Company at its Annual General and Special Meeting (AGM) of Shareholders held on Thursday, December 5, 2013.
COTI-2, a P53 Dependent Treatment for Many Common Cancers, Receives Additional U.S. Patent Protection
Marketwire - Wed Nov 13, 8:03AM CST
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that the United States ("U.S." Patent and Trademark Office has recently granted an additional patent for the Company's lead oncology asset, COTI-2. COTI-2 now has five U.S. patents granted, with several more pending. 
